Crispr Therapeutics AG (CRSP) Stock Price Today
Aura AI Summary
Key Stats
- $5.73BMarket Cap
- -Volume
- HealthSector
- $76.7852W High
- $44.3452W Low
- -Typical Hold Time
- $4.15BEnterprise Value
- -Div Yield
- -Trading Activity
Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $76.78, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Most Recent News
Clearfield remains a buy despite FY2026 guidance cut due to broadband delays and fiber shortages.
Clearfield cut its FY2026 guidance because of delays in broadband projects linked to slow government BEAD program rollout and fiber supply constraints. However, the company secured a $22 million order for hyperscale data centers, validating its growt...
Xiaomi plans $29B R&D from 2026-2030 focusing on AI, chips, and smart ecosystem growth.
Xiaomi will invest $29 billion in research and development between 2026 and 2030, prioritizing advancements in custom artificial intelligence, chips, and operating systems. This investment aims to strengthen its Human x Car x Home ecosystem and boost...
System1 rejects Brave Bison's takeover offer due to undervaluation and unchanged terms.
System1 Group has again rejected Brave Bison's takeover offer, citing that the terms remain unchanged and the offer undervalues System1's shares. Brave Bison's proposal values System1 shares at a discount of 8.2% to the current market price, which Sy...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.